Background: Ensartinib has demonstrated marked efficacy and safety in patients with advanced NSCLC who are ALK tyrosine kinase inhibitor (TKI) naïve and crizotinib resistant and has intracranial activity in the central nervous system (CNS). We report updated data. Method: In this ongoing phase I/II study, patients (pts) with advanced ALK positive NSCLC and measurable disease were given ensartinib 225mg once daily (QD) on a continuous 28-day schedule (NCT01625234). Patients who were either ALK TKI-naïve or had received prior crizotinib and no other ALK TKI received ensartinib until disease progression (PD), unacceptable toxicity or investigator discretion. Patients with asymptomatic brain metastases were allowed to enroll. All pts were assessed for adverse events (AEs) using CTCAE version 4.03, and response was assessed locally every 8 weeks using RECIST 1.1. Results: As of the June 01, 2018 data cutoff, 52 ALK evaluable pts (ALK+ NSCLC pts at 200mg QD with a post baseline response assessment) were assessed (26 male/26 female; median age of 54 (20-80) years; 56% with an ECOG PS of 1). The most common drug-related AEs included rash (54%), nausea (35%), pruritus (31%), vomiting (25%), and fatigue (24%). Most AEs were Grade (G) 1-2. The G3 treatment-related AEs were rash (14%), pruritus (6%), fatigue (3%), decreased appetite (2%), nausea (1%), vomiting (1%), edema (1%), and AST increase (1%). Overall, complete response (CR) or partial response (PR) was achieved in 37 pts, a response rate (RR) of 71%, and 12 pts had stable disease (SD), resulting in a disease control rate (DCR) of 94%. Of the 15 ALK TKI-naïve patients, responses were observed in 12 pts (RR 80%) and 1 had SD, resulting in a DCR of 87%. Interestingly, the 2 pts with PD were ALK FISH-positive via local testing, but negative when analyzed using NGS. In the 37 pts with prior crizotinib but no other ALK TKI, 25 pts responded (1 CR/24 PR) and 1 had SD, resulting in a DCR of 97%. Intracranial responses were observed in 3/3 ALK TKI-naïve pts with target brain lesions at baseline (including 1 CR) and 7/13 crizotinib resistant pts with target lesions at baseline (including 2 CR), resulting in an overall intracranial DCR of 100%. Conclusion: Ensartinib is welltolerated and induces responses in both ALK TKI-naive and crizotinib resistant ALK+ NSCLC pts, as well as patients with CNS lesions. Enrollment in this study and a global phase III study of ensartinib is ongoing. Background: Advances in precision medicine, which treats patients with therapies directed against the specific molecular alterations driving their cancers, have transformed oncology. This approach requires identification of the molecular alterations generating the cancer, the development of targeted therapies, and the validation of companion diagnostics assays to identify patient populations for clinical trials and eventual implementation. In developed countries from North America and Europe, the landscape of the actionable genomic alterations is well known. Thanks to global efforts, such as TCGA or ICGC, today it is possible to establish that a set oncogenic actionable driver mutations (including rearrangement and relevant mutation from KRAS, EGFR, ALK, ERBB2, BRAF, PIK3CA, MET, NRAS, MEK and AKT1) is found in about a 64% of lung adenocarcinomas patients. However, there is still very little information about the molecular epidemiology of lung cancer actionable genes in Latin American patients. Method: The general aims of NIRVANA study (NCT03220230) are the validation of more sensitive and high-throughput technologies for the study of non-small cell lung cancer (NSCLC) genomics alterations, and the generation of a comprehensive, high quality, clinical, pathological, and genomics data of NSCLC in Chile, Brazil and Peru. So far, mutation prevalence of 52 genes (Oncomine Focus Assay, Thermo Fisher Scientific) were analyzed in 1253 NSCLC tumor samples from the NIRVANA Chilean patients. After the variant calling and quality filtering process, potential somatic mutations were annotated against COSMIC, dbSNP and ExAC to classify them as known or novel variants. SIFT and PolyPhen were used to assess the functional impact of the variants. Prevalence is reported within 95% CI of the gene and mutation type level (hotspot or gene fusions). Results: The prevalence of genomic alterations in the 52 genes is similar to previous studies. For example, ALK fusions were present in 3.83% (CI 2.74% -5.32%) of the tumors. Among the 973 DNA variants with a deleterious effect, 63% of them corresponded to novel variants that could be of clinical interest. Compared to the default variant calling process of known variants, this strategy increases by approximately 5-times the potential of finding new mutations for further analyses and new therapeutic opportunities. Conclusion: This work constitutes one of the first approaches towards a comprehensive understanding of NSCLC genomic and actionable mutations in Chilean patients.
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